Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy. Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.
Market Dynamics
Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.
Key features of the study:
- This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nephroblastoma treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market
Detailed Segmentation:
- Global Nephroblastoma Treatment Market, By Type:
- Favorable histology
- Anaplastic histology
- Global Nephroblastoma Treatment Market, By Drug Type:
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
- Global Nephroblastoma Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Nephroblastoma Treatment Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type
- Favorable histology
- Anaplastic histology
- By Drug Type
- Dactinomycin (Cosmegen)
- Doxorubicin (Adriamycin)
- Vincristine (Vincasar PFS, Oncovin)
- Cyclophosphamide (Cytoxan, Neosar)
- Etoposide (Toposar, VePesid)
- Irinotecan (Camptosar)
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck & Co., Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Recordati Rare Diseases
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Actiza Pharmaceutical Private Limited
- Teva Pharmaceutical Industries Ltd.
- Alvogen
- Accord Healthcare Ireland Ltd.
- Baxter
- Amneal Pharmaceuticals LLC.
- Cadila Pharmaceuticals Ltd.
- Company Highlights
- Xediton Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.
